Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions, which are essential for maintaining intracellular osmolarity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance. Dextrose provides glucose for cellular metabolism, and sodium chloride provides sodium and chloride ions for extracellular fluid volume and osmolality maintenance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Replacement of potassium, sodium, chloride, and energy in patients with fluid and electrolyte imbalances,Hypokalemia,Hyponatremia,Intravenous infusion as a source of calories and electrolytes
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion. Rate determined by clinical condition; typical adult maintenance: 100-200 m L/hour, not to exceed 300 m L/hour. Each liter provides potassium 1.5 g (20 m Eq), dextrose 100 g, and sodium chloride 9 g (154 m Eq Na+).
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Potassium: Not applicable; dextrose: 1-2 h (terminal phase); sodium and chloride: not applicable due to homeostatic regulation.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is primarily excreted by the kidneys (90%), with minor losses in feces and sweat. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium and chloride are primarily excreted by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >90% of potassium, chloride, and sodium ions are excreted via kidneys; glucose is fully metabolized or excreted renally if exceeds renal threshold (typically <1% unchanged).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Potassium, sodium, chloride: negligible (<5%); dextrose: not protein-bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Potassium: 0.5–0.6 L/kg (total body water); dextrose: distributes into total body water (0.6 L/kg); sodium and chloride: distributes into extracellular fluid (0.2 L/kg).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR 30-59 m L/min: use cautiously; monitor potassium. GFR 15-29 m L/min: reduce dose by 50% and monitor potassium closely. GFR <15 m L/min: contraindicated unless potassium deficit documented.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B/C: monitor potassium and glucose; adjust rate based on volume status and electrolyte balance.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Infants and children: 0.5-1 m L/kg/hour, max 100 m L/hour. Adjust rate based on weight and clinical need; do not exceed 0.5 m Eq/kg/hour of potassium.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly: lower initial rate (50-100 m L/hour) due to decreased renal function and higher risk of fluid overload; monitor electrolytes and renal function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Intravenous potassium chloride administration may be fatal if given undiluted or in concentrated form. Must be diluted in an appropriate solution and administered slowly. Do not administer unless solution is clear and container is intact.
None.
Use with caution in patients with renal impairment, heart disease, or hyperkalemia,Monitor serum potassium, sodium, glucose, and fluid balance during prolonged therapy,Avoid rapid infusion to prevent hyperkalemia, cardiac arrest, or phlebitis,Do not use in patients with intracranial or intraspinal hemorrhages, or with circulatory overload,Inspect for particulate matter or discoloration before administration
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Renal failure with oliguria or anuria,Hypersensitivity to any component,Severe dehydration,In patients with congestive heart failure when sodium load is detrimental,Cerebral edema
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No direct food interactions. However, dietary potassium intake should be considered when monitoring total potassium balance. Avoid excessive dietary potassium if renal function is compromised.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride, dextrose, and sodium chloride are not teratogenic. No fetal risk is expected from use of this solution at therapeutic doses. Note: Dextrose at high concentrations may cause maternal hyperglycemia, which could theoretically affect fetal development if uncontrolled.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Potassium chloride, dextrose, and sodium chloride are normal constituents of breast milk. No adverse effects on nursing infant are expected. M/P ratio not applicable.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dosing adjustment required for pregnancy. Use standard dosage based on electrolyte and fluid needs, with careful monitoring of serum glucose and electrolytes due to pregnancy-related changes.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This combination solution provides potassium supplementation, free water (via dextrose metabolism), and isotonic sodium chloride. Dextrose 10% is hypertonic (555 m Osm/L) and must be administered via central line to avoid phlebitis. Monitor serum potassium closely, especially in renal impairment. Use with caution in patients with heart failure or hyperkalemia. Do not administer if solution is discolored or contains particulate matter.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This intravenous solution is used to replenish fluids, electrolytes, and energy (calories).,Your healthcare provider will monitor your blood potassium levels regularly during treatment.,Report any symptoms like muscle weakness, irregular heartbeat, or tingling sensations.,Tell your doctor about all medications you are taking, especially diuretics or ACE inhibitors.,Do not stop or adjust the infusion rate on your own.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions, which are essential for maintaining intracellular osmolarity, nerve impulse transmission, cardiac and skeletal muscle contraction, and acid-base balance. Dextrose provides glucose for cellular metabolism, and sodium chloride provides sodium and chloride ions for extracellular fluid volume and osmolality maintenance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion. Rate determined by clinical condition; typical adult maintenance: 100-200 m L/hour, not to exceed 300 m L/hour. Each liter provides potassium 1.5 g (20 m Eq), dextrose 100 g, and sodium chloride 9 g (154 m Eq Na+).. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are not teratogenic. No fetal risk is expected from use of this solution at therapeutic doses. Note: Dextrose at high concentratio. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.